Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials-Reference-Cited by-同舟云学术

Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials

Published:2016-04 Issue:4 Volume:38 Page:843-862.e9
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Sakai Soichi,Kaku Kohei,Seino Yutaka,Inagaki Nobuya,Haneda Masakazu,Sasaki Takashi,Fukatsu Atsushi,Kakiuchi Haruka,Samukawa Yoshishige

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. International Diabetes Federation. IDF Diabetes Atlas, Sixth edition. http://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed February 13, 2015.

2. World Health Organization. BMI Classifications http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed July 1, 2015.

3. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013;Ng;Lancet,2014

4. Japan Diabetes Clinical Data Management Study Group. Basic study. http://jddm.jp/data/index.html. Accessed February 13, 2015.

5. Diagnostic criterion of obesity 2011;J Japan SocStud Obes,2011

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized Controlled Trial on the Effect of Luseogliflozin on Bone Microarchitecture Evaluated Using HR-pQCT in Elderly Type 2 Diabetes;Diabetes Therapy;2024-08-17

2. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus;Diabetology & Metabolic Syndrome;2024-05-12

3. The determination of the comparative effect of Ertugliflozin, Pioglitazone, and Metformin on patients of non-alcoholic fatty liver disease in type 2 diabetes mellitus.;2024-02-28

4. Who benefits from the blood pressure-lowering effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease? — Obese or non-obese?;Hypertension Research;2023-12-15

5. Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study;Clinical Drug Investigation;2023-11-07